3950 JOHNS CREEK COURT, SUWANEE, GA
Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval
Notice of Delisting from Nasdaq Due to Market Value Shortfall
Changes in Board, Management or Compensation
News, Underwriting Agreement, Securities Holder Rights or Indentures
Advances European commercialization strategy following CE mark approval
Announces Second Quarter Financial Results for 2025-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio
Initiation of Access to FemBloc, a Revolutionary Non-Surgical Permanent Contraceptive, as Global Availability Accelerates
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload